文献速递白血病造血干细胞移植与细胞治疗

疾病负荷影响儿童及年轻成人B细胞淋巴细胞白血病接受商业化替沙基仑赛后的结局:儿科真实世界嵌合抗原受体联盟报告

Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report.
PubMed 文献 · J Clin Oncol · 2021-12-09

该回顾性多中心研究纳入15家美国机构200例接受商业化替沙基仑赛的复发/难治B细胞急性淋巴细胞白血病儿童、青少年及年轻成人,意向治疗形态学完全缓解率为79%(95%CI 72-84),输注队列12个月总生存率72%、无事件生存率50%;高疾病负荷与较差的无事件生存和总生存及更高毒性相关。

要点

  • 意向治疗形态学完全缓解率为79%(95%CI 72-84),输注队列完全缓解率为85%(95%CI 79-89)。
  • 输注队列12个月总生存率72%、无事件生存率50%,中位随访335天。
  • 高疾病负荷者12个月总生存率58%、无事件生存率31%,低于低疾病负荷和不可检测疾病者。

核心结论

  • 商业化替沙基仑赛在复发/难治B细胞急性淋巴细胞白血病儿童、青少年及年轻成人中显示有效性和耐受性。
  • 首次按疾病负荷分层的商业化替沙基仑赛分析表明,输注前高疾病负荷与较差的总生存和无事件生存及增加的毒性相关。

研究设计与样本

  • 回顾性、多机构研究,纳入15家美国机构接受白细胞分离术并运送至诺华公司进行商业化替沙基仑赛治疗的复发/难治B细胞急性淋巴细胞白血病儿童、青少年及年轻成人。
  • 200例患者纳入意向治疗缓解分析,185例输注患者纳入生存和毒性分析。

主要发现

  • 意向治疗分析显示形态学完全缓解率为79%(95%CI 72-84)。
  • 输注队列完全缓解率为85%(95%CI 79-89),12个月总生存率为72%,无事件生存率为50%,中位随访335天。
  • 48%的患者在替沙基仑赛前为低疾病负荷(骨髓淋巴母细胞<5%、无CNS3或其他髓外疾病)或不可检测疾病。
  • 单变量和多变量分析显示高疾病负荷(≥5%骨髓淋巴母细胞、CNS3或非中枢神经系统髓外疾病)与较差结局相关,12个月总生存率为58%、无事件生存率为31%,而低疾病负荷者为总生存率85%、无事件生存率70%,不可检测疾病者为总生存率95%、无事件生存率72%(总生存和无事件生存的P<.0001)。
  • 总体3级及以上细胞因子释放综合征和神经毒性发生率分别为21%和7%,高疾病负荷患者中分别为35%和9%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Tisagenlecleucel is a CD19-specific chimeric antigen receptor T-cell therapy, US Food and Drug Administration-approved for children, adolescents, and young adults (CAYA) with relapsed and/or refractory (RR) B-cell acute lymphoblastic leukemia (B-ALL). The US Food and Drug Administration registration for tisagenlecleucel was based on a complete response (CR) rate of 81%, 12-month overall survival (OS) of 76%, and event-free survival (EFS) of 50%. We report clinical outcomes and analyze covariates of outcomes after commercial tisagenlecleucel. METHODS: We conducted a retrospective, multi-institutional study of CAYA with RR B-ALL across 15 US institutions, who underwent leukapheresis shipment to Novartis for commercial tisagenlecleucel. A total of 200 patients were included in an intent-to-treat response analysis, and 185 infused patients were analyzed for survival and toxicity. RESULTS: Intent-to-treat analysis demonstrates a 79% morphologic CR rate (95% CI, 72 to 84). The infused cohort had an 85% CR (95% CI, 79 to 89) and 12-month OS of 72% and EFS of 50%, with 335 days of median follow-up. Notably, 48% of patients had low-disease burden (< 5% bone marrow lymphoblasts, no CNS3, or other extramedullary disease), or undetectable disease, pretisagenlecleucel. Univariate and multivariate analyses associate high-disease burden (HB, ≥ 5% bone marrow lymphoblasts, CNS3, or non-CNS extramedullary) with inferior outcomes, with a 12-month OS of 58% and EFS of 31% compared with low-disease burden (OS; 85%, EFS; 70%) and undetectable disease (OS; 95%, EFS; 72%; P < .0001 for OS and EFS). Grade ≥ 3 cytokine release syndrome and neurotoxicity rates were 21% and 7% overall and 35% and 9% in patients with HB, respectively. CONCLUSION: Commercial tisagenlecleucel in CAYA RR B-ALL demonstrates efficacy and tolerability. This first analysis of commercial tisagenlecleucel stratified by disease burden identifies HB preinfusion to associate with inferior OS and EFS and increased toxicity.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Schultz LM, Baggott C, Prabhu S, et al. Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report. J Clin Oncol. 2021. PMID: 34882493. doi:10.1200/JCO.20.03585

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。